Brief: Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Avalo Therapeutics

27/03/2024 20:13

March 27 (Reuters) - Avalo Therapeutics Inc  AVTX.O :
    * AVALO ACQUIRES ANTI-IL-1Β MAB AND ANNOUNCES PRIVATE
PLACEMENT
FINANCING OF UP TO $185 MILLION
    * AVALO THERAPEUTICS INC: ACQUIRES PHASE 2-READY ANTI-IL-1Β
MAB,
AVTX-009, THROUGH ACQUISITION OF ALMATABIO, INC
    * AVALO THERAPEUTICS INC: TOPLINE RESULTS FROM PLANNED PHASE
2
TRIAL IN HIDRADENITIS SUPPURATIVA EXPECTED IN 2026
    * AVALO THERAPEUTICS INC - EXECUTED PRIVATE PLACEMENT
FINANCING OF
UP TO $185 MILLION, INCLUDING INITIAL UPFRONT INVESTMENT OF
$115.6 MILLION
    * AVALO THERAPEUTICS INC: UPFRONT FUNDING IS EXPECTED TO
FUND
OPERATIONS THROUGH DATA READOUT AND INTO 2027
    * AVALO THERAPEUTICS INC: INTENDS TO DEVELOP AVTX-009 IN AT
LEAST
ONE OTHER CHRONIC INFLAMMATORY INDICATION

Source text for Eikon:  ID:nGNXbFhbPt 
Further company coverage:  AVTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))